Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November.
This week institutions bought calls worth more than 10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price!
They also have a big partnership with the giant Roche Holding AG (RHHBY).
I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon!
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.